Süleyman Serdar KOCA, İbrahim Hanifi ÖZERCAN, Ebru ÖNALAN ETEM, Osman ÇİFTÇİ, Neşe BAŞAK TÜRKMEN, Ahmet YILDIRIM, Demet YALÇIN KEHRİBAR, Metin ÖZGEN, Servet YOLBAŞ

The inhibition of Src kinase suppresses the production of matrix metalloproteinases in from synovial fibroblasts and inhibits MAPK and STATs pathways

Background/aim: The purpose of this study was to investigate the antiarthritic potentials of the inhibition of Src kinase in vivo and in vitro settings. Materials and methods: Arthritis was induced by intradermal injection of chicken type II collagen combined with incomplete Freund’s adjuvant (collagen induced arthritis [CIA] model) in Wistar albino rats. One day after the onset of arthritis, dasatinib, a potent Src kinase inhibitor, (5 mg/kg/day) was given via oral gavage. Tissue Src, Fyn, MAPK and STAT mRNA expressions were determined by real-time polymerase chain reaction. On the other hand, fibroblast like synoviocytes (FLSs) were harvested patients with rheumatoid arthritis (RA) undergoing surgical knee joint replacement. FLSs were stimulated with cytokines and dasatinib was added in different concentrations. MMP –1, –3, and –13 levels in FLSs culture were determined by ELISA. Results: The tissue mRNA expressions of Src, Fyn, MAPK and STATs were increased in the arthritis CIA group compared to the control group. Their mRNA expressions in the CIA + dasatinib group were decreased and similar in the control group. In in vitro setting, MMP –1, –3, and –13 expressions from FLSs induced by IL-1β and TNF-α were increased, while dasatinib suppressed their productions from FLSs. Conclusion: The present study shows that the inhibition of Src kinase has antiarthritic potentials in both in vivo and in vitro settings. Src kinase inhibition may be candidate to further research in human RA.Key words: Rheumatoid arthritis, collagen induced arthritis, src kinase, matrix metalloproteinase

PDF

___

1. Bellucci E, Terenzi R, La Paglia GM, Gentileschi S, Tripoli A et al. One year in review 2016: pathogenesis of rheumatoid arthritis. Clinical and Experimental Rheumatology 2016; 34 (5): 793-801.
2. Kim K, Bang SY, Lee HS, Bae SC. Update on the genetic architecture of rheumatoid arthritis. Nature Reviews Rheumatology 2017; 13 (1): 13-24. doi: 10.1038/ nrrheum.2016.176
3. Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nature Reviews Rheumatology 2016; 12 (8): 472-485. doi: 10.1038/ nrrheum.2016.91
4. Calabrò A, Caterino AL, Elefante E, Valentini V, Vitale A et al. One year in review 2016: novelties in the treatment of rheumatoid arthritis. Clinical and Experimental Rheumatology 2016; 34 (3): 357-372.
5. Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Design Development and Therapy 2015; 9 (9): 773-779. doi: 10.2147/DDDT.S80207
6. Byeon SE, Yi YS, Oh J, Yoo BC, Hong S et al. The role of Src kinase in macrophage-mediated inflammatory responses. Mediators of Inflammation 2012; 2012:512926. doi: 10.1155/2012/512926
7. Liu ST, Pham H, Pandol SJ, Ptasznik A. Src as the link between inflammation and cancer. Frontiers in Physiology 2014; 4 (4): 416. doi: 10.3389/fphys.2013.00416
8. Christopher L, Scott K. The Src family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clinical Colorectal Cancer 2010; 9 (2): 89-94. doi: 10.3816/CCC.2010.n.012
9. Shahrara S, Castro-Rueda HP, Haines GK, Koch AE. Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues. Arthritis Research & Therapy 2007; 9 (5): R112. doi: 10.1186/ar2318
10. Takayanagi H, Juji T, Miyazaki T, Iizuka H, Takahashi T et al. Suppression of arthritic bone destruction by adenovirusmediated csk gene transfer to synoviocytes and osteoclasts. Journal of Clinical Investigation 1999; 104 (2): 137-146. doi: 10.1172/JCI6093
11. Ozgen M, Koca SS, Karatas A, Dagli AF, Erman F et al. Lapatinib ameliorates experimental arthritis in rats. Inflammation 2015; 38 (1): 252-259. doi: 10.1007/s10753-014-0028-6.12
12. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. Journal of Experimental Medicine 1977; 146 (3): 857-868. doi: 10.1084/ jem.146.3.857
13. Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. Journal of Bone and Mineral Research 2010; 25 (8): 1759-1770. doi: 10.1002/jbmr.85
14. Barsante MM, Roffê E, Yokoro CM, Tafuri WL, Souza DG et al. Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. European Journal of Pharmacology 2005; 516 (3): 282-289. doi: 10.1016/j. ejphar.2005.05.005
15. Huber LC, Künzler P, Boyce SH, Michel BA, Gay RE et al. Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases 2008; 67: 389-394. doi: 10.1136/ard.2007.072330
16. Paunovic V, Harnett MM. Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis. Drugs 2013; 73 (2): 101-115. doi: 10.1007/s40265-013-0014-6
17. Kunisch E, Gandesiri M, Fuhrmann R, Roth A, Winter R et al. Predominant activation of MAP kinases and prodestructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007; 66 (8): 1043-1051. doi: 10.1136/ard.2006.062521
18. Summy JM, Trevino JG, Baker CH, Gallick GE. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 2005; 31 (3): 263-274. doi: 10.1097/01.mpa.0000178280.50534.0c
19. Yang CM, Lee IT, Lin CC, Wang CH, Cherng WJ et al. c-Srcdependent MAPKs/AP-1 activation is involved in TNF-αinduced matrix metalloproteinase-9 expression in rat heartderived H9c2 cells. Biochemical Pharmacology 2013; 85 (8): 1115-1123. doi: 10.1016/j.bcp.2013.01.013
20. Tan YH, Li K, Chen XY, Cao Y, Light AR et al. Activation of Src family kinases in spinal microglia contributes to formalin-induced persistent pain state through p38 pathway. The Journal of Pain 2012; 13 (10): 1008-1015. doi: 10.1016/j. jpain.2012.07.010
21. Haura EB. SRC and STAT pathways. Journal of Thoracic Oncology 2006; 1 (5): 403-405.
22. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. The Journal of Rheumatology 2005; 32 (9): 1650- 1653.
23. Oike T, Sato Y, Kobayashi T, Miyamoto K, Nakamura S et al. Stat3 as a potential therapeutic target for rheumatoid arthritis. Scientific Reports 2017; 7 (1): 10965. doi: 10.1038/s41598-017- 11233-w
24. Schreiner SJ, Schiavone AP, Smithgall TE. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. The Journal of Biological Chemistry 2002; 277 (47): 45680- 45687. doi: 10.1074/jbc.M204255200
25. Kovács M, Németh T, Jakus Z, Sitaru C, Simon E et al. The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. Journal of Experimental Medicine 2014; 211 (10): 1993-2011. doi: 10.1084/jem.20132496
26. To WS, Aungier SR, Cartwright AJ, Ito K, Midwood KS. Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells. British Journal of Pharmacology 2015; 172 (15): 3805- 3816. doi: 10.1111/bph.13170
27. Kramer B, Schultz JD, Hock C, Sauter A, Stuck BA et al. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma. Oncology Letters 2017; 13 (5): 3269-3276. doi: 10.3892/ol.2017.5844
28. Huang J, Xie B, Li Q, Xie X, Zhu S et al. Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis. European Journal of Pharmacology